Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Doebele

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2012
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancerR C Doebele, P Conkling, A M Traynor, et al.
NPJ Precision Oncology|October 13, 2021
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLCT L Peters, T Patil, A T Le, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2022
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLCA A Bokhari, W-Y Lai, A T Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2019
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibY Wang, T Jiang, Z Qin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Nature Medicine|October 29, 2013
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerA Vaishnavi, M Capelletti, A T Le, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2012
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancerR C Doebele, P Conkling, A M Traynor, et al.
NPJ Precision Oncology|October 13, 2021
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLCT L Peters, T Patil, A T Le, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2022
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLCA A Bokhari, W-Y Lai, A T Le, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2019
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibY Wang, T Jiang, Z Qin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation studyD S Hong, T M Bauer, J J Lee, et al.
Nature Medicine|October 29, 2013
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerA Vaishnavi, M Capelletti, A T Le, et al.
Pageof 2